Evaluation of an antibiotic intravenous to oral sequential therapy program

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 1, 2005, Pages 53-59

  Pablos, Ana I ^a   Escobar, Ismael ^a   Albiñana, Sandra ^a   Serrano, Olga ^a   Ferrari, José M ^a   de Tejada, Alberto Herreros ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Ciprofloxacin; DDD; Economic; Levofloxacin; Ofloxacin; Quinolones; Sequential therapy

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN;

ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG HALF LIFE; DRUG USE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; ECONOMICS, PHARMACEUTICAL; FORMULARIES, HOSPITAL; HUMANS; INJECTIONS, INTRAVENOUS; QUINOLONES; SPAIN; TIME FACTORS;

EID: 11844297823     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1042     Document Type: Article

References (14)

1. Paladino JA. Pharmacoeconomics of antimicrobial therapy. Am J Health Syst Pharm 1999; 56: S25-S28.
2. Nathwani D, Tillotson G. Sequential antimicrobial therapy - the role of quinolones. J Antimicrob Chemother 1997; 39: 441-446.
3. Davey P, Nathwani D. Sequential antibiotic therapy: the right patient, the right time and the right outcome. J Infect 1998; 37 37-44.
4. Grasela TH, Paladino JA. Clinical and economic impact of oral ciprolloxacin as follow-up to parenteral antibiotics. Ann Pharmacother 1991; 25: 857-862.
5. Przybylski KG, Rybak MJ. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 1997; 17(2): 271-276.
6. Gangji D, Jacobs F. Brief report: randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gram-negative septicemia. Am J Med 1989; 87 5A-206S-5A-208S.
7. Thummel KE, Shen DD. Design and optimization of dosage regimens: pharmacokinetic data. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, Hardman JG, Limbird LE, Goodman Gilman A (eds). The McGraw-Hill Companies, Inc.: New York, NY 2001.
8. MacGowan AP, Bowker KE. Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. J Infect 1998; 37: 30-36.
9. Paladino JA, Sperry HE. Clinical and economic evaluation of oral ciprolloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462-470.
10. Chrysanthopoulos CJ, Starakis JC. Brief report: sequential intravenous/oral therapy with ciprofloxacin in severe infection. Am J Med 1989; 87: 5A-225S-5A-227S.
11. Amodio-Groton M, Madu A. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Ann Pharmacother 1996; 30: 596-602.
12. Daly JS, Worthington MG. Brief report: intravenous and sequential intravenous and oral ciprofloxacin in the treatment of severe infections. Am J Med 1989; 87: 5A-232S-5A-234S.
13. Partsch DJ, Paladino JA. Cost.effectiveness comparison of sequential ofloxacin versus standard switch therapy. Ann Pharmacother 1997; 31: 1137-1145.
14. Janknegt R, Van der Meer JWM. Antimicrobial practice sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994; 33: 169-177.